Insider filing
Traded Oct 1 · filed 25 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SLDB · NASDAQ · Biological Products, (No Diagnostic Substances)
Solid Biosciences (SLDB) · oqro.io/stocks/SLDB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$6.25−0.19 (−2.95%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Including 5 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider filing
Traded Oct 1 · filed 25 days later
Compensation award — excluded from discretionary-purchase analysis.
Gabriel Brooks (Chief Medical Officer) sold ~$25K of Solid Biosciences
Automatic saleTraded Oct 18, 2026 · largest single transaction 9,750
Oct 18, 20269,750
DetailsOfficial recordOct 18, 2026
Traded Oct 2, 2026 · largest single transaction 3,440
Oct 2, 20263,440
DetailsOfficial recordOct 2, 20263,440
Insider buying
Traded Mar 11, 2025 · filed 2 days later
A Solid Biosciences director paid $9.9K out of pocket for Solid Biosciences shares. 3 other people at Solid Biosciences bought some too, in the same month. Shares held went up 169% with this purchase.
Insider buying
Traded Feb 19, 2025 · filed 2 days later
A Solid Biosciences director paid $20.1M out of pocket for Solid Biosciences shares. 3 other people at Solid Biosciences bought some too, in the same month. Shares held went up 73% with this purchase.
Insider buying
Traded Feb 19, 2025 · filed 2 days later
A major shareholder of Solid Biosciences paid $4.03M out of pocket for Solid Biosciences shares. 3 other people at Solid Biosciences bought some too, in the same month. Shares held went up 25% with this purchase.
Insider buying
Traded Feb 18, 2025 · filed 1 day later
A major shareholder of Solid Biosciences paid $1.91M out of pocket for Solid Biosciences shares. 3 other people at Solid Biosciences bought some too, in the same month. Shares held went up 6% with this purchase.
Alexander Cumbo (President and CEO) sold ~$45K of Solid Biosciences
Automatic saleKevin Tan (CFO & Treasurer) sold ~$13K of Solid Biosciences
Automatic saleDavid T Howton (Chief Operating Officer) sold ~$22K of Solid Biosciences
Automatic saleIlan Ganot (Director) sold ~$6.8K of Solid Biosciences
Automatic saleGabriel Brooks (Chief Medical Officer) sold ~$13K of Solid Biosciences
Automatic saleJessie Hanrahan (Chief Regulatory Officer) sold ~$12K of Solid Biosciences
Automatic salePaul Herzich (Chief Technology Officer) sold ~$11K of Solid Biosciences
Automatic saleIlan Ganot (Director) sold ~$448 of Solid Biosciences
Automatic saleKevin Tan (CFO & Treasurer) sold ~$16K of Solid Biosciences
Automatic saleIlan Ganot (Director) sold ~$4.6K of Solid Biosciences
Automatic saleAlexander Cumbo (President and CEO) sold ~$62K of Solid Biosciences
Automatic saleDavid T Howton (Chief Operating Officer) sold ~$28K of Solid Biosciences
Automatic saleJessie Hanrahan (Chief Regulatory Officer) sold ~$26K of Solid Biosciences
Automatic salePaul Herzich (Chief Technology Officer) sold ~$16K of Solid Biosciences
Automatic saleGabriel Brooks (Chief Medical Officer) sold ~$19K of Solid Biosciences
Automatic sale4 open-market purchases and 16 open-market sales by insiders of SLDB between Dec 9, 2023 and today, placed against the company's last 4 earnings releases. The latest on file was filed Mar 6, 2026. The data provider lists the next release for Mar 4, 2027; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Mar 6, 2026 | None | None | None |
| Nov 3, 2025 | None | None | None |
| Feb 18, 2025 | 8 sales | 1 purchase | 3 purchases |
| Jan 8, 2024 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies